《大行報告》野村下調中國平安(02318.HK)目標價至83.17元 評級「買入」
野村發表報告表示,中國平安(02318.HK)去年稅後經營利潤按年增長爲6.1%至1,480億元人民幣,符合該行預期,當中經營淨資產收益率按年降1個百分點至19%;派息爲2.38元,增8%,高於該行預期;人壽新業務價值則降24%至379億元人民幣,低於該行預期。
報告又指,受內地對金融科技行業的監管收緊,預料集團實施的技術戰略將退居二線,惟對集團的財務並沒有任何影響,因爲其上市科技子公司僅佔集團目前總市值的5%。
該行維持中國平安(02318.HK)「買入」評級,目標價由85.56元下調至83.17元,並預測集團在2022年的營運利潤增長爲3%,而該股現價相當於今年預測內涵價值比率的0.6倍,及股息收益率5.1%。(ca/s)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.